Dendreon stock sinks as analysts downgrade on debt concerns, dwindling prospects for cancer drug

Dendreon continued to watch its stock decline Wednesday, a day after the Seattle company announced it might not be able to repay a looming debt of $620 million when it comes due in early 2016...